Exelixis is an oncology company that develops medicines for difficult-to-treat cancers. It offers CABOMETYX and COMETRIQ tablets and capsules for various types of cancer. The company also offers COTELLIC and MINNEBRO for specific forms of melanoma and hypertension. Exelixis is developing zanzalintinib and XB002, next-generation oral tyrosine kinase inhibitors. It has research collaborations and license agreements with several pharmaceutical companies. The company was incorporated in 1994 and is headquartered in Alameda, California.
Indicator | Value |
---|---|
PER | 24.2 |
EV/EBITDA | 15.7 |
Price/Free Cash Flow' | 19.9 |
ROIC | 28.7% |
Net Debt/EBITDA | -0.0 |